[ad_1]
In an interview with the Russian ambassador to Moldova, Oleg Vasnetsov, Moldovan President Maia Sandu said that her priority task was to guarantee the access of the country’s citizens to the coronavirus vaccine “as many species as possible”.
Moldova wants to get help from Russia for the fastest possible access to the Russian vaccine against the Sputnik V coronavirus. This was stated by the president of Moldova, Maia Sandu, during a meeting with the Russian ambassador in Moldova, Oleg Vasnetsov, reported his service of press on March 25.
“The priority now is to ensure that our citizens have access to as many types of effective vaccines as possible. We reiterate, as in other discussions, that we want to get help from the Russian Federation for faster access to the Sputnik V vaccine, given the need to accelerate the process The sooner we guarantee public access to the COVID-19 vaccine, the sooner we will have the opportunity to return to normal life and save the lives of our loved ones, ”he said.
In Moldova, according to the American Johns Hopkins University, the coronavirus was confirmed in almost 220 thousand people, 4661 patients died, 193.6 thousand cases were recovered.
Vaccination against the cornavirus in Moldova began on March 2. At that time, the country received about 20,000 doses of the vaccine produced by AstraZeneca. On March 19, Moldova received 24.6 thousand doses of the Pfizer / BioNTech vaccine. through the global COVAX initiative. According to Bloomberg, 27.4 thousand vaccines against the coronavirus were carried out in the country (the population of Moldova is 2.6 million people).
The Sputnik V vaccine was registered in Russia on August 11 last year. Russian President Vladimir Putin argued that it is effective, forms a stable immunity and has passed all the tests.
The vaccine has received criticism in the scientific community, since it was registered before the third phase of clinical trials. In Russia, they claimed to be 95 percent effective. The international journal The Lancet wrote an efficiency of 91.6%.
At the same time, several Russian scientists pointed out that the accelerated approach to vaccine registration is contrary to scientific and ethical standards for drug development. The vaccinated Russians complained of various side effects: fever, loss of smell, high blood pressure.
The Sputnik V vaccine has not been approved in the European Union. In Russia, a mass vaccination with a national drug is being carried out. On March 23, the Sputnik V vaccine was approved for use in 56 countries, according to Russia’s Direct Investment Fund.
The head of the European Commission, Ursula von der Leyen, during a speech in Brussels on February 17, expressed surprise that Russia is offering Sputnik V to other countries without vaccinating its own population.
[ad_2]
